Results 21 to 30 of about 101,548 (353)

Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants

Diabetes, obesity and metabolism, 2023
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of orforglipron (LY3502970), an oral, non‐peptide glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) in healthy participants.
E. Pratt, Xiaosu Ma, Rong Liu, D. Robins, A. Haupt, T. Coskun, K. Sloop, C. Benson   +7 more
semanticscholar   +1 more source

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

Diabetes, obesity and metabolism, 2023
To evaluate the tolerability, safety and pharmacodynamics of different dose‐escalation schemes of the oral small‐molecule glucagon‐like peptide‐1 receptor (GLP‐1R) agonist danuglipron.
A. Saxena, J. Frias, Donal N. Gorman, Rene N Lopez, Nabil Andrawis, N. Tsamandouras, M. Birnbaum   +6 more
semanticscholar   +1 more source

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity

Frontiers in Endocrinology, 2023
The occurrence of obesity is an increasing issue worldwide, especially in industrialized countries. Weight loss is important both to treat obesity and to prevent the development of complications.
I. Zaffina, M. Pelle, G. Armentaro, F. Giofrè, V. Cassano, A. Sciacqua, Franco Arturi   +6 more
semanticscholar   +1 more source

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Nature Communications, 2022
Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D.
Hongwei Jiang, Shuguang Pang, Yawei Zhang, Ting Yu, Meng Liu, Huan Deng, Li Li, Liqi Feng, Baili Song, Han Han-Zhang, Qingyang Ma, Lei Qian, Wenying Yang   +12 more
doaj   +1 more source

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu, Guillaume Mabilleau, Iepsen, Iepsen, Marie Pereira   +4 more
core   +5 more sources

Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]

, 2014
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond, Watterson, Kenneth R.   +3 more
core   +2 more sources

A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)

Scientific Reports, 2021
Treatment options for nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), two conditions which coexist, are limited though weight loss is an important strategy to improve outcomes in either disease.
S. Ghosal, Debasis Datta, B. Sinha
semanticscholar   +1 more source

The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma [PDF]

Exploration of Asthma & Allergy
Glucagon-like peptide-1 (GLP-1) is a hormone that regulates blood glucose levels and is produced by the enteroendocrine glands in the large and small intestines in response to the consumption of foods that contain carbohydrates, fats, and proteins.
Courtney Lehman, Ray Stokes Peebles Jr
doaj   +1 more source

Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation

Neural Regeneration Research, 2020
Glucagon-like peptide-1 receptor has anti-apoptotic, anti-inflammatory, and neuroprotective effects. It is now recognized that the occurrence and development of chronic pain are strongly associated with anti-inflammatory responses; however, it is not ...
Shan-Shan Cui, Xiao-Bo Feng, Bing-Hong Zhang, Zhong-Yuan Xia, Li-Ying Zhan   +4 more
doaj   +1 more source

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi, Anetzberger, Anichini, Aoyama, Baggio, Balint, Ban, Beckman, Bouxsein, Brunton, Chen, Coleman, Dempster, Ealey, Eckel, Feng, Flatt, Friedman, Griffith, Griffith, Hamilton, Hu, Karim, Kim, Lee, Lu, Ma, Mabilleau, Mabilleau, Mansur, Marenzana, Mieczkowska, Napoli, Nuche-Berenguer, Nuche-Berenguer, Nuche-Berenguer, Nystrom, Nystrom, Odgaard, Okerson, Orland, Orriss, Paschalis, Pereira, Pereira, Prisby, Richard, Roche, Roszer, Schalkwijk, Scheller, Selley, Shymkiw, Smits, Stabley, Sun, Tartaglia, Upadhyay, van Bloemendaal, Vijan, Williams, Wu, Yamamoto, Yamamoto, Yamamoto   +64 more
core   +6 more sources